Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections

Diagn Microbiol Infect Dis. 1992 May-Jun;15(4 Suppl):119S-122S. doi: 10.1016/0732-8893(92)90138-j.

Abstract

Roxithromycin 300 mg once daily was compared with clarithromycin 250 mg b.i.d. in an open randomized trial in 200 patients with upper respiratory tract infection: sinusitis, pharyngotonsillitis, and otitis media. Average treatment duration was 9 days. Roxithromycin was more effective (p less than 0.01) particularly in otitis media and pharyngotonsillitis, and better tolerated (only 4% side effects, p less than 0.05).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Clarithromycin
  • Drug Tolerance
  • Erythromycin / administration & dosage
  • Erythromycin / adverse effects
  • Erythromycin / analogs & derivatives*
  • Erythromycin / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Otitis Media / drug therapy
  • Pharyngitis / drug therapy
  • Respiratory Tract Infections / drug therapy*
  • Roxithromycin / administration & dosage
  • Roxithromycin / adverse effects
  • Roxithromycin / therapeutic use*
  • Sinusitis / drug therapy
  • Tonsillitis / drug therapy

Substances

  • Roxithromycin
  • Erythromycin
  • Clarithromycin